Thirty-four years in practice teaches you to be careful with predictions about eye care. Some of the things that were going to change everything did, quietly, over fifteen years rather than two. Others were on magazine covers and then disappeared. So rather than a list of exciting technologies, here is an attempt to sort what is coming by how confident anyone should reasonably be about it.
Already happening, and will keep spreading
Myopia control in children. This is the most important change in eye care in a generation, and it involves no lasers at all. Short-sightedness in Indian schoolchildren has risen sharply, and high myopia is not a spectacle problem, it is a lifelong risk factor for retinal detachment, glaucoma and macular degeneration. We now have three approaches that measurably slow how fast a child's eyes elongate: low-concentration atropine drops, spectacle lenses with a peripheral defocus design, and specific contact lens options. None stops myopia. Each buys a meaningful reduction, and starting at eight rather than fourteen changes the arithmetic considerably. Expect this to become routine in paediatric eye care rather than specialist.
Screening leaving the hospital. Retinal cameras have become small, cheap and easy enough to use that photographs can be taken in a diabetes clinic, a corporate office or a district camp and read elsewhere. Combined with automated triage, this reaches people who would never have travelled to an eye hospital until their vision had already gone. In a country where diabetes is common and diabetic retinopathy is silent until late, this is the single highest-value use of new technology we have.
Cataract surgery getting more precise rather than more dramatic. The operation itself is already excellent: a few minutes, no stitches, walk out the same day. The remaining gains are in accuracy, better biometry, better lens power prediction, better astigmatism management, so that more people land exactly on the refractive target rather than close to it. Useful, incremental, unglamorous. Most improvements in cataract surgery over the next decade will look like this.
Likely within ten years
- Fewer injections for retinal disease. Treatment for diabetic macular oedema and wet age-related macular degeneration works well, but it means repeated injections, often monthly at the start. Longer-acting molecules and slow-release implants are the main direction of research, and they are progressing. Halving the number of hospital visits would change adherence dramatically, which in turn changes outcomes. Anyone under long-term retinal care will feel this before they feel anything else on this page.
- Better lens options for reading vision. Multifocal and extended-depth lenses today involve a genuine trade-off between spectacle independence and night-time glare. Lenses that actually change focus inside the eye, rather than splitting light between distance and near, are in development. If they arrive and work, the cataract conversation becomes much simpler.
- Gene therapy for inherited retinal disease. This is real, not speculative. One gene therapy for a rare inherited retinal condition has been approved abroad, and more are in trials. The caution is scope and cost: these treat specific rare mutations, not common blindness, and current pricing runs into crores per eye. Availability in India will lag approval by years. Still, a category that was untreatable for a century is no longer entirely untreatable.
- Corneal work becoming more modular. Transplanting only the diseased layer instead of the whole cornea is already standard practice in corneal surgery, and cross-linking has changed keratoconus from a slow slide towards transplant into something usually stopped early. Expect that direction to continue: smaller interventions, earlier.
Promising, but currently oversold
This section matters more than the previous two, because this is where patients lose money.
- Bionic eyes and retinal implants. Genuine science, decades of work, and results so far that are far below what the phrase suggests. Recipients perceive patterns of light, not images. Some major programmes have been discontinued, leaving implanted patients without support. This will probably arrive eventually. It has not arrived.
- Presbyopia eye drops. They exist and they do something. The effect is modest, lasts a few hours, works best in a narrow band of patients, and can cause dim vision and brow ache. Useful for a specific person on a specific evening. Not a replacement for reading glasses.
- Stem cell treatment for optic nerve damage or retinitis pigmentosa. Be blunt about this one. There are clinics in India and elsewhere charging large sums for injections claimed to restore vision lost to optic atrophy or inherited retinal disease. Outside a registered clinical trial, there is no established treatment of this kind, there is documented harm, and the money is gone either way. If someone promises to restore vision an ophthalmologist has called permanent, ask which peer-reviewed trial they are quoting and who is paying whom.
- Anything advertised as a cure for glaucoma damage. Nerve fibres already lost do not come back. Everything we do in glaucoma protects what remains. New drops, new laser techniques and new drainage devices will all improve, and all of them will still be about protection.
What will not change
Two things, and they are the ones that decide most outcomes.
First, the diseases that cause most blindness in India remain silent until late. Glaucoma takes the periphery first and you do not notice. Diabetic retinopathy causes no symptom at all until it bleeds or the macula swells. No device changes this. Only a scheduled examination does, which is why the recommendation stays boring: a full check at 40, every year or two after that, and yearly from diagnosis if you have diabetes regardless of how well you see.
Second, someone has to examine the eye. Better imaging means a specialist sees more, not that fewer specialists are needed. The decisions, whether to operate, when to wait, what a particular patient can live with, remain human ones. That is the part of eye care that has not changed since 1993 and probably will not in the next decade.
The useful takeaway is not to wait for any of this. The treatments that will prevent the most blindness over the next ten years are the ones already sitting in clinics today, applied earlier. If you are over 40, diabetic, or have a parent with glaucoma, book a full examination rather than watching the technology news. Our five centres across Telangana and Andhra Pradesh are open for that.
